Effects of Telmisartan/Hydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

One of the most common adverse effects resulting from the therapy with thiazides, thiazide-like diuretics and loop diuretics is increased potassium secretion. Disregulation of plasma potassium may be a life-threatening condition due to increased risk of arrythmias. Moreover, it has been postulated that decrease in plasma potassium level may negatively affect glucose metabolism resulting in the increased risk of new-onset type 2 diabetes.The main goal of this study is to assess the efficacy and safety of telmisartan/hydrochlorothiazide in a broad population of hypertensive patients, including the effects of the therapy on plasma potassium level and also on selected parameters of glucose and lipid metabolism.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Hydrochlorothiazide; Telmisartan; Telmisartan, hydrochlorothiazide drug combination

Criteria

Inclusion Criteria:

• primary hypertension

• age>18 years

Exclusion Criteria:

• Cholestatic disorders or severe hepatic/renal failure

• allergy to telmisartan or hydrochlorothiazide

• treatment-resistant hypokalemia or hypercalcemia

• pregnancy and lactation period